ONCR earnings

Company now focused on the development of ONCR-021, Oncorus' lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company's cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeli

ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumorsRecommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is underwayThree of eight evaluable patients at RP2D across multiple indications (cutaneous melanoma, head and neck cancer, and mucosal melanoma) experienced clinical benefit after two doses of single-agent ONCR-177Proof of principle established for propriety Herpes Simplex Virus (HSV) platform that leverages microRNA attenuation to enable interferon resistance via retention of γ34.5 and five complementary immunomo

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced details of its upcoming presentation of initial data from the ongoing Phase 1 dose escalation and expansion clinical trial of ONCR-177 at the upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place November 12–14, 2021 in Washington, D.C. and virtually. ONCR-177, Oncorus' lead product candidate built on the company's oncolytic Herpes Simplex Virus (HSV) platform, is an intratumorally administered viral immunotherapy being developed for the treatment of multiple